The serotonin transporter, gender, and 17β oestradiol in the development of pulmonary arterial hypertension

Cardiovascular Research

Volumn 90, Issue 2, 2011, Pages 373-382

  White, Kevin ^a   Dempsie, Yvonne ^a   Nilsen, Margaret ^a   Wright, Audrey F ^a   Loughlin, Lynn ^a   MacLean, Margaret R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

17 oestradiol; Gender; Oestrogen; Pulmonary arterial hypertension; Serotonin

Indexed keywords

2,3,6,7 TETRAHYDRO 1' METHYL 5 [[2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL) 4 BIPHENYLYL]CARBONYL]SPIRO[FURO[2,3 F]INDOLE 3,4' PIPERIDINE]; ESTRADIOL; FENCLONINE; SEROTONIN 1B RECEPTOR; SEROTONIN TRANSPORTER; TRYPTOPHAN HYDROXYLASE;

ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR RISK; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DISEASE COURSE; ENZYME REGULATION; FEMALE; GENDER; HEART LEFT VENTRICLE CONTRACTION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HYPOXIA; LUNG ARTERY; MALE; MOUSE; NONHUMAN; OVARIECTOMY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PULMONARY HYPERTENSION; SEROTONINERGIC SYSTEM; SMOOTH MUSCLE FIBER; UPREGULATION;

ANIMALS; ANOXIA; CELL DIVISION; CELLS, CULTURED; ESTRADIOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, MUTANT STRAINS; MUSCLE, SMOOTH, VASCULAR; OVARIECTOMY; PHENOTYPE; PULMONARY ARTERY; RECEPTOR, SEROTONIN, 5-HT1B; RISK FACTORS; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEX DISTRIBUTION;

EID: 79955369537     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq408     Document Type: Article

References (47)

1. Newman JH, Trembath RC, Morse JA, Grunig E, Loyd JE, Adnot S et al. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol 2004;43:33-39.
2. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007;30:104-109. (Pubitemid 47074013)
3. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-1030.
4. Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry for pul-monary arterial hypertension: 1982-2006. Eur Respir J 2007;30:1103-1110. (Pubitemid 351194756)
5. Masi AT. Editorial: pulmonary hypertension and oral contraceptive usage. Chest 1976; 69:451-453.
6. Morse JH, Horn EM, Barst RJ. Hormone replacement therapy: a possible risk factor in carriers of familial primary pulmonary hypertension. Chest 1999;116:847. (Pubitemid 29428518)
7. Rajkumar R, Konishi K, Richards T, Ishizawar D, Wiechert A, Kaminski N et al. Genome-wide RNA expression profiling in lung identifies distinct signatures in idio-pathic pulmonary arterial hypertension and secondary pulmonary hypertension. Am J Physiol Heart Circ Physiol 2010;298:1235-1248.
8. Austin ED, Cogan JD, West JD, Hedges LK, Hamid R, Dawson EP et al. Alterations in oestrogen metabolism: implications for higher penetrance offamilial pulmonary arter-ial hypertension in females. Eur Respir J 2009;34:1093-1099.
9. Rabinovitch M, Gamble WJ, Miettinen OS, Reid L. Age and sex influence on pulmonary-hypertension of chronic hypoxia and on recovery. Am J Physiol 1981; 240:H62-H72.
10. Resta TC, Kanagy NL, Walker BR. Estradiol-induced attenuation of pulmonary hyper-tension is not associated with altered eNOS expression. Am J Physiol Lung Cell Mol Physiol 2001;280:L88-L97.
11. Hansmann G, Wagner RA, Schellong S, Perez VA, Urashima T, Wang L et al. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxi-some proliferator-activated receptor-gamma activation. Circulation 2007;115: 1275-1284. (Pubitemid 46594772)
12. Morecroft I, Dempsie Y, Bader M, Walther DJ, Kotnik K, Loughlin L et al. Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pul-monary hypertension. Hypertension 2007;49:232-236. (Pubitemid 46360365)
13. Dempsie Y, Morecroft I, Welsh DJ, Macritchie NA, Herold N, Loughlin L et al. Con-verging evidence in support ofthe serotonin hypothesis ofdexfenfluramine-induced pulmonary hypertension with novel transgenic mice. Circulation 2008;117:2928-2937. (Pubitemid 351787078)
14. Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001;108:1141-1150. (Pubitemid 32995372)
15. Morecroft I, Heeley RP, Prentice HM, Kirk A, MacLean MR. 5-hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: impor-tance ofthe 5-HT1B receptor. Br J Pharmacol 1999;128:730-734. (Pubitemid 29504766)
16. Morecroft I, Pang L, Baranowska M, Nilsen M, Loughlin L, Dempsie Y et al. In vivo effects of a combined 5-HT1B receptor/SERT antagonist in experimental pulmonary hypertension. Cardiovasc Res 2010;85:593-603.
17. Pecins-Thompson M, Brown NA, Kohama SG, Bethea CL Ovarian steroid regulation oftryptophan hydroxylase mRNA expression in rhesus macaques. J Neurosci 1996;16: 7021-7029. (Pubitemid 26359381)
18. Lu NZ, Eshleman AJ, Janowsky A, Bethea CL Ovarian steroid regulation ofserotonin reuptake transporter (SERT) binding, distribution, and function in female macaques. Mol Psychiatry 2003;8:353-360. (Pubitemid 36712930)
19. MacLean MR, Deuchar GA, Hicks MN, Morecroft I, Shen SB, Sheward J et al. Over-expression ofthe 5-hydroxytryptamine transporter gene: effect on pulmonary hemo-dynamics and hypoxia-induced pulmonary hypertension. Circulation 2004;109: 2150-2155. (Pubitemid 38620226)
20. Karas RH, Schulten H, Pare G, Aronovitz MJ, Ohlsson C, Gustafsson JA et al. Effects of estrogen on the vascular injury response in estrogen receptor alpha, beta (double) knockout mice. Circ Res 2001;89:534-539. (Pubitemid 34133991)
21. Keegan A, Morecroft I, Smillie D, Hicks MN, MacLean MR. Contribution of the 5-HT1B receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-HT1B-receptor knockout mice and the 5-HT1B/1D-receptor antagonist GR127935. Circ Res 2001;89:1231-1239. (Pubitemid 34627883)
22. Farhat MY, Chen MF, Bhatti T, Iqbal A, Cathapermal S, Ramwell PW. Protection by oestradiol against the development of cardiovascular changes associated with mono-crotaline pulmonary hypertension in rats. Br J Pharmacol 1993;110:719-723. (Pubitemid 23279284)
23. Dempsie Y, Macritchie NA, Morecroft I, Nilsen M, Loughlin L, MacLean MR. The effects of gender on the development of dexfenfluramine-induced pulmonary arterial hypertension in mice. Am J Respir Crit Care Med 2009;179:A1808.
24. Dempsie Y, White K, Nilsen M, Loughlin L, MacLean MR. The effects of endogenous female sex hormones on dexfenfluramine-induced pulmonary arterial hypertension in mice. Am J Respir Crit Care Med 2010;181:A6314.
25. Tofovic SP, Rafikova O. Preventive and therapeutic effects of 2-methoxyestradiol, but not estradiol, in severe occlusive pulmonary arterial hypertension in female rats. Am J Respir Crit Care Med 2009;179:A1802.
26. Lawrie A, Spiekerkoetter E, Martinez EC, Ambartsumian N, Sheward WJ, MacLean MR et al. Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. Circ Res 2005;97:227-235. (Pubitemid 41105448)
27. Yang J, Davies RJ, Southwood M, Long L, Yang X, Sobolewski A et al. Mutations in bone morphogenetic protein type II receptor cause dysregulation of Id gene expression in pulmonary artery smooth muscle cells: implications for familial pulmon-ary arterial hypertension 3. Circ Res 2008;102:1212-1221.
28. Farhat MY, Vargas R, Dingaan B, Ramwell PW. In vitro effect of oestradiol on thymi-dine uptake in pulmonary vascular smooth muscle cell: role ofthe endothelium. Br J Pharmacol 1992;107:679-683.
29. Rosselli M, Imthurm B, Macas E, Keller PJ, Dubey RK. Circulating nitrite/nitrate levels increase with follicular development indirect evidence for estradiol-mediated no release. Biochem Biophys Res Commun 1994;202:1543-1552.
30. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998;19:1-27. (Pubitemid 28376821)
31. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differ-ences in estrogen hydroxylation activity. Cancer Res 2000;60:3440-3444. (Pubitemid 30482162)
32. Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estro-gens and its regulation in human. Cancer Lett 2005;227:115-124. (Pubitemid 41174580)
33. Tofovic SP, Zhang XC, Jackson EK, Dacic S, Petrusevska G. 2-Methoxyestradiol med-iates the protective effects of estradiol in monocrotaline-induced pulmonary hyper-tension. Vascul Pharmacol 2006;45:358-367. (Pubitemid 44765298)
34. Swaneck GE, Fishman J. Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci USA 1988;85: 7831-7835.
35. Lahm T, Crisostomo PR, Markel TA, Wang M, Wang Y, Weil B et al. Exogenous estro-gen rapidly attenuates pulmonary artery vasoreactivity and acute hypoxic pulmonary vasoconstriction. Shock 2008;30:660-667.
36. MacRitchie AN, Jun SS, Chen Z, German Z, Yuhanna IS, Sherman TS et al. Estrogen upregulates endothelial nitric oxide synthase gene expression in fetal pulmonary artery endothelium. Circ Res 1997;81:355-362. (Pubitemid 27362522)
37. Earley S, Resta TC. Estradiol attenuates hypoxia-induced pulmonary endothelin-1 gene expression. Am J Physiol Lung Cell Mol Physiol 2002;283:L86-L93. (Pubitemid 34764544)
38. Eddahibi S, Guignabert C, Barlier-Mur AM, Dewachter L, Fadel E, Dartevelle P et al. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation 2006;113: 1857-1864. (Pubitemid 43739397)
39. Long L, MacLean MR, Jeffery TK, Morecroft I, Yang XD, Rudarakanchana N et al. Ser-otonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res 2006;98:818-827.
40. Eddahibi S, Raffestin B, Pham I, Launay JM, Aegerter P, Sitbon M et al. Treatment with 5-HT potentiates development of pulmonary hypertension in chronically hypoxic rats. Am J Physiol Heart Circ Physiol 1997;41:H1173-H1181.
41. Machado RD, Koehler R, Glissmeyer E, Veal C, Suntharalingam J, Kim M et al. Genetic association of the serotonin transporter in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;173:793-797.
42. Willers ED, Newman JH, Loyd JE, Robbins IM, Wheeler LA, Prince MA et al. Seroto-nin transporter polymorphisms in familial and idiopathic pulmonary arterial hyperten-sion. Am J Respir Crit Care Med 2006;173:798-802.
43. Eddahibi S, Hanoun N, Lanfumey L, Lesch KP, Raffestin B, Hamon M et al. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transpor-ter gene. J Clin Invest 2000;105:1555-1562. (Pubitemid 30390306)
44. Kilic A, Javadov S, Karmazyn M. Estrogen exerts concentration-dependent pro-and anti-hypertrophic effects on adult cultured ventricular myocytes. Role of NHE-1 in estrogen-induced hypertrophy. J Mol Cell Cardiol 2009;46:360-369.
45. Nebigil CG, Etienne N, Messaddeq N, Maroteaux L Serotonin is a novel survival factor of cardiomyocytes: mitochondria as a target of 5-HT2B-receptor signaling. FASEBJ 2003;17:1373-1375.
46. Williams RS. Apoptosis and heart failure 2. N Engl J Med 1999;341:759-760.
47. Morecroft I, Loughlin L, Nilsen M, Colston J, Dempsie Y, Sheward J et al. Functional interactions between 5-hydroxytryptamine receptors and the serotonin transporter in pulmonary arteries. J Pharmacol Exp Ther 2005;313:539-548. (Pubitemid 40604152)